Dance Biopharm

Dance Biopharm is a biopharmaceutical company focused on developing inhaled insulin products to treat diabetes patients worldwide. The company's main product candidates include Dance 501, a second-phase clinical trial drug/device combination product, and a pocket-sized inhaler device with an insulin container, designed to control blood glucose levels in diabetes patients without the need for injections.